Autoantibody to tumor antigen, alpha 2-HS glycoprotein: A novel biomarker of breast cancer screening and diagnosis

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 5, 2009, Pages 1357-1364

  Jae, Kyo Yi ^a   Jong, Wook Chang ^b   Han, Wonshik ^a   Jong, Won Lee ^a   Ko, Eunyoung ^a   Dong, Hyun Kim ^b   Bae, Ji Yeon ^a   Yu, Jonghan ^a   Lee, Cheolju ^b   Yu, Myeong Hee ^b   Noh, Dong Young ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; FETUIN A; TUMOR ANTIGEN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN URINE LEVEL; SENSITIVITY AND SPECIFICITY; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ADULT; ANTIGENS, NEOPLASM; BLOOD PROTEINS; BLOTTING, WESTERN; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 66549089699     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0696     Document Type: Article

References (46)

1. Chu KC, Tarone RE, Kessler LG, et al. Recent trends in U S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 1996;88:1571-1579 (Pubitemid 26374510)
2. Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN. Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 1995;87:1681-1685
3. Tabar L, Fagerberg CJ, Gad A, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1985;1:829-832 (Pubitemid 15115114)
4. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996;14:2843-2877 (Pubitemid 26329672)
5. Hu S, Loo JA, Wong DT. Human body fluid proteome analysis. Proteomics 2006;6:6326-6353 (Pubitemid 44935518)
6. Downes MR, Byrne JC, Dunn MJ, Fitzpatrick JM, Watson RW, Pennington SR. Application of proteomic strategies to the identification of urinary biomarkers for prostate cancer: a review. Biomarkers 2006;11:406-416 (Pubitemid 44364080)
7. Chang JW, Kang UB, Kim DH, et al. Identification of circulating endorepellin LG3 fragment: potential use as a serological biomarker for breast cancer. Proteomics Clin Appl 2008;2:23-32.
8. Caron M, Choquet-Kastylevsky G, Joubert-Caron R. Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics 2007;6:1115-1122 (Pubitemid 47099223)
9. Volkmann M, Sinn HP, Gaugel D, et al. Anti-p53 in breast cancer: concordance of different assay procedures and association with p53 antigen expression. Oncology 2002;63:297-305. (Pubitemid 36151325)
10. Duffy MJ. CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem 1999;36:579-586 (Pubitemid 29410709)
11. Brichory FM, Misek DE, Yim AM, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A 2001;98:9824-9829 (Pubitemid 32769388)
12. Chang JW, Lee SH, Jeong JY, et al. Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small cell lung cancer. FEBS Lett 2005;579:2873-2877
13. Fujita Y, Nakanishi T, Hiramatsu M, et al. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res 2006;12:6415-6420 (Pubitemid 44799713)
14. Hong SH, Misek DE, Wang H, et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 2004;64:5504-5510 (Pubitemid 39006575)
15. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997;15:3363-3367 (Pubitemid 27485856)
16. Le Naour F, Misek DE, Krause MC, et al. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 2001;7:3328-3335 (Pubitemid 33069962)
17. von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, et al. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur J Cancer 1996;32A:1325-1331 (Pubitemid 26246705)
18. Menard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 2000;182:150-162 (Pubitemid 30022667)
19. Disis ML, Cheever MA. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res 1997;71:343-371 (Pubitemid 27197763)
20. Hutchinson JN, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt-1 (PKB-A) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res 2004;64:3171-3178 (Pubitemid 38581419)
21. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5312
22. Pieper R, Gatlin CL, McGrath AM, et al. Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 2004;4:1159-1174 (Pubitemid 38445973)
23. Lenner P, Wiklund F, Emdin SO, et al. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. Br J Cancer 1999;79:927-932 (Pubitemid 29082128)
24. Gourevitch MM, von Mensdorff-Pouilly S, Litvinov SV, et al. Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br J Cancer 1995;72:934-938
25. Conroy SE, Sasieni PD, Fentiman I, Latchman DS. Autoantibodies to the 90kDa heat shock protein and poor survival in breast cancer patients. Eur J Cancer 1998;34:942-943 (Pubitemid 128716718)
26. Jameel A, Skilton RA, Campbell TA, Chander SK, Coombes RC, Luqmani YA. Clinical and biological significance of HSP89 α in human breast cancer. Int J Cancer 1992;50:409-415
27. Metcalfe S, Wheeler TK, Picken S, Negus S, Jo Milner A. P53 autoantibodies in 1006 patients followed up for breast cancer. Breast Cancer Res 2000;2:438-443 (Pubitemid 32223641)
28. Canelle L, Bousquet J, Pionneau C, et al. An efficient proteomics-based approach for the screening of autoantibodies. J Immunol Methods 2005;299:77-89. (Pubitemid 40725925)
29. van Dalen A. Pre-operative tumour marker levels in patients with breast cancer and their prognosis. Tumour Biol 1990;11:189-195 (Pubitemid 20292239)
30. Dnistrian AM, Schwartz MK, Greenberg EJ, Smith CA, Schwartz DC. Evaluation of CA M26, CA M29, CA 15-3 and CEA as circulating tumor markers in breast cancer patients. Tumour Biol 1991;12:82-90.
31. van Dalen A. Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 21.1 in metastatic disease. Anticancer research 1996;16:2345-2349
32. Molina R, Jo J, Filella X, et al. c-erbB-2 oncoprotein, CEA, CA 15.3 in patients with breast cancer: prognostic value. Breast cancer research and treatment 1998;51:109-119 (Pubitemid 28561416)
33. Gion M, Mione R, Leon AE, et al. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer 2001;37:355-363 (Pubitemid 32182324)
34. Molina R, Barak V, van Dalen A, et al. Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol 2005;26:281-293 (Pubitemid 41619458)
35. Mocellin S, Rossi CR, Nitti D, Lise M, Marincola FM. Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines. Biochim Biophys Acta 2003;1653:61-71. (Pubitemid 37487648)
36. Sugi T, Makino T. Autoantibodies to contact proteins in patients with recurrent pregnancy losses. J Reprod Immunol 2002;53:269-277 (Pubitemid 34569222)
37. Carlsson L, Ronquist G, Nilsson BO, Larsson A. Dominant prostasome immunogens for sperm-agglutinating autoantibodies of infertile men. J Androl 2004;25:699-705. (Pubitemid 39096303)
38. Bosscher JR, Gercel-Taylor C, Watkins CS, Taylor DD. Epitope recognition by anti-cathepsin D autoantibodies in endometrial cancer patients. Gynecol Oncol 2001;81:138-143 (Pubitemid 32424151)
39. Wilson KS, Roberts H, Leek R, Harris AL, Geradts J. Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Am J Pathol 2002;161:1171-1185
40. Chen SH, Arany I, Apisarnthanarax N, et al. Response of keratinocytes from normal and psoriatic epidermis to interferon-γ differs in the expression of zinc-α(2)-glycoprotein and cathepsin D. FASEB J 2000;14:565-571
41. Swallow CJ, Partridge EA, Macmillan JC, et al. α2HS-glycoprotein, an antagonist of transforming growth factor β in vivo, inhibits intestinal tumor progression. Cancer Res 2004;64:6402-6409 (Pubitemid 39297893)
42. Wang H, Zhang M, Bianchi M, Sherry B, Sama A, Tracey KJ. Fetuin (α2-HS-glycoprotein) opsonizes cationic macrophagedeactivating molecules. Proc Natl Acad Sci U S A 1998;95:14429-14434
43. Szweras M, Liu D, Partridge EA, et al. α 2-HS glycoprotein/fetuin, a transforming growth factor-β/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem 2002;277:19991-19997 (Pubitemid 34967522)
44. Srinivas PR, Wagner AS, Reddy LV, et al. Serum α 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol 1993;7:1445-1455 (Pubitemid 2021156)
45. Mathews ST, Chellam N, Srinivas PR, et al. α2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Mol Cell Endocrinol 2000;164:87-98. (Pubitemid 30665503)
46. Anderson L, Anderson NG. High resolution two-dimensional electrophoresis of human plasma proteins. Proc Natl Acad Sci U S A 1977;74:5421-5425